Real‐World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population‐Based Study
Head & Neck · 14.11.2026
DOI: 10.1002/hed.70547 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, online erschienen am 14.11.2026. Verfasst von Phoebe L Sault und 3 weiteren Autor:innen. Beteiligte Einrichtung: Sydney Pharmacy School, The University of Sydney, Camperdown, New South Wales, Australia. Die Arbeit nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Nivolumab is an immune checkpoint inhibitor used for recurrent/metastatic squamous cell carcinoma (SCC) of the oral cavity, pharynx, and larynx; yet Australian real‐world evidence remains limited.
Methods
A retrospective cohort study was conducted using linked Pharmaceutical Benefits Scheme dispensing and National Death Index mortality data for patients initiating nivolumab monotherapy during 2019–2023. Overall survival (OS), time to treatment discontinuation (TTD), and dispensing‐based proxies for potential immune‐related adverse events (irAEs) were assessed.
Results
Among 1398 patients, median OS was 9.3 months and TTD was 7.8 months. Median OS was longer in males than females (10.0 vs. 7.7 months, p = 0.049), while patients with prior corticosteroid exposure had shorter OS than those without (8.3 vs. 11.5 months; aHR 1.20, 95% CI: 1.06–1.36). Incident corticosteroid and levothyroxine use occurred in 10.3% and 10.9% of patients, respectively.
Conclusions
Real‐world outcomes were comparable to clinical trial findings, supporting nivolumab's effectiveness in Australian clinical practice.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sydney Pharmacy School, The University of Sydney, Camperdown, New South Wales, Australia.
- Real-World Precision Medicines Research Group, Kolling Institute, Faculty of Medicine and Health, The University of Sydney and the Northern Sydney Local Health District, Sydney, New South Wales, Australia.
- Pharmaceutical Policy Node, Charles Perkins Centre, The University of Sydney, Sydney, New South Wales, Australia.
- Department of Pharmacy, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, Australia.
ORCID-Profile: Phoebe L Sault, Chin Hang Yiu, Edwin C K Tan, Christine Y Lu
Zitieren
APA
Sault, P. L., Yiu, C. H., Tan, E. C. K., & Lu, C. Y. (2026). Real‐World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population‐Based Study. Head & Neck. https://doi.org/10.1002/hed.70547
Vancouver
Sault PL, Yiu CH, Tan ECK, Lu CY. Real‐World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population‐Based Study. Head & Neck. 2026. doi:10.1002/hed.70547
BibTeX
@article{Sault2026,
author = {Sault, Phoebe L and Yiu, Chin Hang and Tan, Edwin C K and Lu, Christine Y},
title = {Real‐World Outcomes of Nivolumab in Recurrent/Metastatic Squamous Cell Carcinoma of the Oral Cavity, Pharynx, and Larynx: An Australian Population‐Based Study},
journal = {Head & Neck},
year = {2026},
doi = {10.1002/hed.70547}
}
EUVIMED